Patrick Wood
Stock Analyst at Morgan Stanley
(3.34)
# 955
Out of 4,783 analysts
81
Total ratings
50%
Success rate
4.29%
Average return
Main Sectors:
Stocks Rated by Patrick Wood
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TFX Teleflex | Maintains: Overweight | $275 → $191 | $139.33 | +37.08% | 4 | Mar 5, 2025 | |
| SOLV Solventum | Maintains: Equal-Weight | $73 → $80 | $75.51 | +5.95% | 4 | Mar 5, 2025 | |
| TNDM Tandem Diabetes Care | Downgrades: Equal-Weight | $45 → $22 | $19.81 | +11.06% | 4 | Mar 5, 2025 | |
| PRCT PROCEPT BioRobotics | Maintains: Overweight | $105 → $95 | $61.76 | +53.82% | 2 | Feb 26, 2025 | |
| DXCM DexCom | Maintains: Equal-Weight | $75 → $82 | $69.47 | +18.04% | 7 | Feb 14, 2025 | |
| EW Edwards Lifesciences | Maintains: Equal-Weight | $70 → $75 | $71.19 | +5.35% | 8 | Feb 12, 2025 | |
| BSX Boston Scientific | Maintains: Overweight | $100 → $120 | $100.80 | +19.05% | 5 | Feb 6, 2025 | |
| COO The Cooper Companies | Maintains: Equal-Weight | $104 → $102 | $84.98 | +20.03% | 5 | Dec 6, 2024 | |
| GKOS Glaukos | Downgrades: Underweight | $120 | $103.57 | +15.86% | 3 | Dec 2, 2024 | |
| BLCO Bausch + Lomb | Downgrades: Equal-Weight | $19 | $15.00 | +26.67% | 6 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $234 → $317 | $260.27 | +21.80% | 5 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $10 | $6.59 | +51.75% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $104 → $145 | $70.44 | +105.85% | 1 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $65 → $85 | $96.80 | -12.19% | 3 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $37 | $17.57 | +110.59% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $39 → $30 | $33.70 | -10.98% | 3 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $74 → $86 | $81.66 | +5.31% | 5 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $225 → $215 | $224.23 | -4.12% | 3 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $310 → $280 | $228.71 | +22.43% | 3 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $26.67 | +34.98% | 1 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $152.50 | - | 5 | Dec 11, 2017 |
Teleflex
Mar 5, 2025
Maintains: Overweight
Price Target: $275 → $191
Current: $139.33
Upside: +37.08%
Solventum
Mar 5, 2025
Maintains: Equal-Weight
Price Target: $73 → $80
Current: $75.51
Upside: +5.95%
Tandem Diabetes Care
Mar 5, 2025
Downgrades: Equal-Weight
Price Target: $45 → $22
Current: $19.81
Upside: +11.06%
PROCEPT BioRobotics
Feb 26, 2025
Maintains: Overweight
Price Target: $105 → $95
Current: $61.76
Upside: +53.82%
DexCom
Feb 14, 2025
Maintains: Equal-Weight
Price Target: $75 → $82
Current: $69.47
Upside: +18.04%
Edwards Lifesciences
Feb 12, 2025
Maintains: Equal-Weight
Price Target: $70 → $75
Current: $71.19
Upside: +5.35%
Boston Scientific
Feb 6, 2025
Maintains: Overweight
Price Target: $100 → $120
Current: $100.80
Upside: +19.05%
The Cooper Companies
Dec 6, 2024
Maintains: Equal-Weight
Price Target: $104 → $102
Current: $84.98
Upside: +20.03%
Glaukos
Dec 2, 2024
Downgrades: Underweight
Price Target: $120
Current: $103.57
Upside: +15.86%
Bausch + Lomb
Dec 2, 2024
Downgrades: Equal-Weight
Price Target: $19
Current: $15.00
Upside: +26.67%
Nov 11, 2024
Maintains: Overweight
Price Target: $234 → $317
Current: $260.27
Upside: +21.80%
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $18 → $10
Current: $6.59
Upside: +51.75%
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $104 → $145
Current: $70.44
Upside: +105.85%
Jul 15, 2024
Upgrades: Equal-Weight
Price Target: $65 → $85
Current: $96.80
Upside: -12.19%
Jul 15, 2024
Downgrades: Underweight
Price Target: $50 → $37
Current: $17.57
Upside: +110.59%
Jul 15, 2024
Downgrades: Underweight
Price Target: $39 → $30
Current: $33.70
Upside: -10.98%
Feb 12, 2024
Maintains: Equal-Weight
Price Target: $74 → $86
Current: $81.66
Upside: +5.31%
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $225 → $215
Current: $224.23
Upside: -4.12%
Dec 4, 2023
Maintains: Overweight
Price Target: $310 → $280
Current: $228.71
Upside: +22.43%
Dec 4, 2023
Initiates: Overweight
Price Target: $36
Current: $26.67
Upside: +34.98%
Dec 11, 2017
Upgrades: Buy
Price Target: n/a
Current: $152.50
Upside: -